Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival.
Omer S KarrarMaymona AbdelmagidMasooma RanaMoazah IftikharMcCullough KristenAref A Al-KaliHassan B AlkhateebKebede H BegnaMichelle A ElliottAbhishek A MangaonkarAntoine N SalibaMehrdad HefaziMark R LitzowWilliam HoganMithun Vinod ShahMirinal S PatnaikAnimesh D PardananiTalha BadarHemant S MurthyJames ForanJeanne PalmerLisa SproatNandita KheraCecilia Y Arana YiAyalew TefferiNaseema GangatPublished in: American journal of hematology (2023)
Overall survival and response rates of 270 patients with newly diagnosed acute myeloid leukemia receiving venetoclax (Ven) plus hypomethylating agent, stratified by Ven dosing schedule (Cycle 1 Ven 14 vs. 21 vs. 28 days).